Matches in Wikidata for { <http://www.wikidata.org/entity/Q87078099> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q87078099 description "assaig clínic" @default.
- Q87078099 description "clinical trial" @default.
- Q87078099 description "clinical trial" @default.
- Q87078099 description "clinical trial" @default.
- Q87078099 description "clinical trial" @default.
- Q87078099 description "ensaio clínico" @default.
- Q87078099 description "ensayo clínico" @default.
- Q87078099 description "ensayu clínicu" @default.
- Q87078099 description "essai clinique" @default.
- Q87078099 description "klinisch onderzoek" @default.
- Q87078099 description "клінічне випробування" @default.
- Q87078099 description "կլինիկական փորձարկում" @default.
- Q87078099 name "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 name "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 type Item @default.
- Q87078099 label "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 label "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 prefLabel "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 prefLabel "PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery" @default.
- Q87078099 P1050 Q87078099-5CE12421-625B-46D5-A985-7EE50BF8FA8B @default.
- Q87078099 P1132 Q87078099-89E28141-DE9B-4F5B-93AD-F6DC08680AD1 @default.
- Q87078099 P1476 Q87078099-678617C5-ADE3-445F-B7AC-F73759576CF4 @default.
- Q87078099 P2899 Q87078099-6CBD05E2-35EE-4DF6-84AD-09F99ECA3D25 @default.
- Q87078099 P3098 Q87078099-4452BA2D-54B6-43ED-810C-46D31FA4AE06 @default.
- Q87078099 P31 Q87078099-2F41DBEB-A0EF-4DBD-98EA-11F9945FD7EF @default.
- Q87078099 P4135 Q87078099-8EF5591D-8ED1-4F15-AFDA-5B2377806D73 @default.
- Q87078099 P4844 Q87078099-4420772D-D96B-46EB-8C54-66F8DFF4F2BA @default.
- Q87078099 P4844 Q87078099-6C15BD31-9342-4535-B0A2-D2D3FC82D701 @default.
- Q87078099 P4844 Q87078099-CF870387-7F45-4438-9C64-57CFCF985AC0 @default.
- Q87078099 P580 Q87078099-5E60BCFE-DBC5-4700-9028-84A52BCA6F87 @default.
- Q87078099 P582 Q87078099-FCEAB415-E73A-49FD-9E6E-041BE6D6432F @default.
- Q87078099 P6099 Q87078099-17E43C47-097D-4C30-9BAC-AF631DF1199F @default.
- Q87078099 P8363 Q87078099-F98A7DA7-75DB-4705-890A-F391B62A4EAD @default.
- Q87078099 P921 Q87078099-27331CCF-6FC8-4D5A-9B76-8D707210A049 @default.
- Q87078099 P1050 Q124292 @default.
- Q87078099 P1132 "+67" @default.
- Q87078099 P1476 "Effect of PD-1 Antibody (SHR-1210) Combined With Apatinib and Capecitabine Treatment After Resection of Intrahepatic Cholangiocarcinoma With High Risk of Recurrence : a Phase 2 Study." @default.
- Q87078099 P2899 "+18" @default.
- Q87078099 P3098 "NCT04295317" @default.
- Q87078099 P31 Q30612 @default.
- Q87078099 P4135 "+75" @default.
- Q87078099 P4844 Q27262801 @default.
- Q87078099 P4844 Q420207 @default.
- Q87078099 P4844 Q66559285 @default.
- Q87078099 P580 "2020-02-01T00:00:00Z" @default.
- Q87078099 P582 "2021-12-31T00:00:00Z" @default.
- Q87078099 P6099 Q42824440 @default.
- Q87078099 P8363 Q78089383 @default.
- Q87078099 P921 Q2481887 @default.